Collegium at Jefferies Conference: Strategic Growth and Market Positioning

At the Jefferies Global Healthcare Conference 2025, Collegium Pharmaceutical (COLL) projected an 18% increase in 2025 net sales, aiming for $735 million to $750 million, driven by growth in its ADHD drug Jornay PM and a focus on its pain management portfolio. The company highlighted the durability of its revenue streams, with patent exclusivity for Xtampza ER extending to September 2033, and plans to continue strategic share repurchases and debt reduction, targeting a leverage ratio of less than 1x net debt/EBITDA by year-end 2025. Collegium reported strong Q1 2025 results, with revenue up 23% year-over-year to $177 million and $55 million in cash from operations.

Analysis

Collegium Pharmaceutical (NASDAQ:COLL) presented a robust strategic outlook at the Jefferies Global Healthcare Conference, projecting an 18% increase in net sales for 2025 to a range of $735 million to $750 million, up from $631 million in 2024. This growth is underpinned by strong Q1 2025 performance, where revenue reached $177 million, a 23% year-over-year increase, and cash from operations was $55 million. A key driver is Jornay PM, an ADHD treatment, which achieved over $100 million in 2024 sales and is targeted for over $135 million in 2025, supported by an expanded sales force from 125 to 180 representatives as of April 2025 and increased marketing efforts focused on the back-to-school season. The company emphasized the durability of its pain management portfolio, including Xtampza ER (patent exclusivity through September 2033), BELBUCA ($211 million sales in 2024), and the Nucynta franchise ($177 million sales in 2024), asserting that no single generic competitor has met all criteria for market entry. Collegium is actively enhancing shareholder value through strategic share repurchases, including a $25 million program announced in May 2025, and aims to reduce its leverage ratio to less than 1x net debt/EBITDA by the end of 2025 from 1.5x at Q1 2025. The company maintains high profitability, with adjusted EBITDA margins exceeding 60% and projected 2025 adjusted EBITDA between $435 million and $450 million, while its U.S.-centric operations provide insulation from international pricing pressures and tariffs.

Key Decisions for Investors

• Investors should evaluate Collegium's ability to achieve its 18% net sales growth target for 2025, driven significantly by Jornay PM's performance following sales force expansion and increased marketing.
• Close monitoring of Jornay PM's prescription growth (24% YoY in Q1 2025) and market share gains, especially during the Q3 back-to-school season and into Q4, will be crucial for validating the impact of recent investments.
• The company's progress towards its sub-1x net debt/EBITDA leverage target by year-end 2025 and ongoing share repurchase activity are key metrics for assessing financial health and commitment to shareholder return.
• The asserted durability of the pain management portfolio, particularly the patent exclusivity for key products like Xtampza ER through September 2033, warrants continued attention in light of potential generic competition and evolving market dynamics.